FDA approves Humira biosimilar, but it won't hit the market for 4 years - Becker's Hospital Review

FDA approves Humira biosimilar, but it won't hit the market for 4 years  Becker's Hospital Review

The FDA has approved Hadlima, a biosimilar to AbbVie's blockbuster rheumatoid arthritis treatment Humira. However, it won't be available in the U.S. until June ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases